title: Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results.
abstract: This study was undertaken to identify the clinical value of incidentally detected lesions (IDLs) in the gastrointestinal tract (GIT) with (18)F-FDG PET/CT.
  
  
  METHODS
  The reported database of 3,281 patients who underwent partial-body (18)F-FDG PET/CT scans from April 2001 to September 2003 was reviewed. Patients with incidental (18)F-FDG accumulations in the GIT that were associated with concomitant abnormal soft-tissue density or wall thickening on the native CT were evaluated. Incidental PET/CT findings were correlated with endoscopic and histopathologic results.
  
  
  RESULTS
  According to our selection criteria, 98 (3%) of the 3,281 patients had an IDL of the GIT on (18)F-FDG PET/CT. Correlative endoscopic findings were available in 69 (70%) of 98 patients. Of these, 13 patients (19%) were harboring newly occurring cancers of the GIT in addition to preexisting aerodigestive tract tumors (n = 12) and malignant melanoma (n = 1). Twenty-nine (42%) patients were identified with precancerous lesions, such as advanced colonic adenomas (n = 27), Barrett's esophagus (n = 1), and intestinal metaplasia of the gastric mucosa (n = 1). Inflammatory and other benign GIT lesions were detected in 12 (17%) and 6 (8%) patients, respectively. In 9 (13%) patients, PET/CT was false-positive, showing normal findings in subsequent endoscopic examinations. In 20 (28%) of 69 patients, PET/CT findings had a relevant impact on the clinical management. Twenty-nine (30%) of the 98 patients were not subject to a further endoscopic examination because of the extent and nature of the primary tumor (n = 17), loss to follow-up (n = 7), death shortly after PET (n = 3), and patient unwillingness (n = 2).
  
  
  CONCLUSIONS
  Although IDLs of the GIT on (18)F-FDG PET/CT scans are found only in about 3% of cases, they are associated with a substantial risk of an underlying cancerous or precancerous lesion. Early identification of these occult lesions may have a major impact on the patients' management and outcome.
authors.affiliation: Nuclear Medicine, Department of Medical Radiology, University Hospital of Zurich, CH-8091 Zurich, Switzerland.
authors.forename: Ehab M
authors.initials: EM
authors.lastname: Kamel
authors.forename: Miriam
authors.initials: M
authors.lastname: Thumshirn
authors.forename: Kaspar
authors.initials: K
authors.lastname: Truninger
authors.forename: Marc
authors.initials: M
authors.lastname: Schiesser
authors.forename: Michael
authors.initials: M
authors.lastname: Fried
authors.forename: Barbara
authors.initials: B
authors.lastname: Padberg
authors.forename: Didier
authors.initials: D
authors.lastname: Schneiter
authors.forename: Sandro J
authors.initials: SJ
authors.lastname: Stoeckli
authors.forename: Gustav K
authors.initials: GK
authors.lastname: von Schulthess
authors.forename: Katrin D M
authors.initials: KD
authors.lastname: Stumpe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016145:Endoscopy, Digestive System; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D041981:Gastrointestinal Tract / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D006801:Humans; D033162:Incidental Findings; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic; D013382:Subtraction Technique; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18